LSD-derived anxiety drug shows promise in trial, yet regulatory, equity, and historical contexts dictate its real impact
Original framing: “Definium says LSD-based pill reduces anxiety in late-stage study - Reuters” — Reuters (via Google News)
The criminalization of psychedelics in the 1960s, driven by political fear‑mongering, created a research vacuum that is only now being reopened. Historical parallels to the opioid crisis show how market‑driven rollouts can exacerbate inequities when safeguards are absent. Understanding these legacies is essential to avoid repeating past harms.
The Reuters story spotlights a promising LSD‑derived anxiety pill but neglects the intertwined histories of criminalization, Indigenous stewardship, and systemic inequities that shape its real-world impact.
By weaving Indigenous epistemologies, historical lessons, cross‑cultural set‑and‑setting, and rigorous scientific scrutiny, we see that efficacy alone cannot guarantee equitable access. Trickster insight reveals the absurdity of commodifying a sacred plant without addressing the power structures that have long marginalized its original custodians. Implementing publicly funded integration clinics, equitable knowledge partnerships, regulatory reforms, and open‑access longitudinal research can transform this breakthrough into a just, culturally resonant public health advance.